Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247207 | 0.87 | P2RX7 (1.00) | P2RX7ABCB11 | |
| SCHEMBL6290790 | 0.86 | P2RX7 (0.95) | P2RX7ABCB11 | |
| SCHEMBL6247451 | 0.83 | P2RX7 (0.80) | P2RX7ABCB11 | |
| SCHEMBL6248279 | 0.83 | P2RX7 (0.80) | P2RX7ABCB11 | |
| SCHEMBL1412853 | 0.82 | P2RX7 (0.76) | P2RX7ABCB11 | |
| SCHEMBL1412940 | 0.80 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL6246639 | 0.79 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL6247714 | 0.78 | P2RX7 (0.83) | P2RX7ABCB11 | |
| SCHEMBL1412966 | 0.78 | P2RX7 (0.59) | P2RX7ABCB11 | |
| SCHEMBL1412831 | 0.76 | P2RX7 (0.51) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310493-B1 | N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6927219-B2 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003042190-A1 | N-ALKYL-ADAMANTYL DERIVATIVES AS P2X7-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1310493-A1 | N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists | Pfizer Products Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | AIFM1, BAD, BID | P2RX7 1205/4885ABCB11 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.